NSE: TTKHLTCARE · BSE: 507747 · ISIN INE910C01018
TTK Healthcare Limited stock analysis
TTK Healthcare Limited ranks #3423 in the TickerSutra evidence-ranked universe with a score of 40/100 and 95% data confidence. The latest captured fundamentals show ROCE of 8.0%, quarterly sales growth of 13.8% and quarterly profit growth of 63.7%.Avoid / exit review
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.02×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹599cr | ₹22cr | ₹42cr | 3.6% |
| 2023 | ₹725cr | ₹31cr | ₹640cr | 4.3% |
| 2024 | ₹753cr | ₹37cr | ₹63cr | 5.0% |
| 2025 | ₹801cr | ₹35cr | ₹82cr | 4.3% |
| 2026 | ₹857cr | ₹26cr | ₹66cr | 3.0% |
| TTM | ₹888cr | ₹38cr | ₹74cr | 4.3% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Both the Jaipur and Hosakote Plants received global Non-GMO (Genetically Modified Organism) Project’s Verified Certification for one product each. The Division continues to improve operational efficiency through TPM (Total Productive Maintenance), while focusing on value-added products to enhance profitability, undertaking capacity expansion projects and investing in critical spares and innovative equipment designs t
Your Company continues to be one of the pre-qualified suppliers under the WHO-UNFPA Pre-Qualification Scheme for Male Latex Condoms, a critical requirement for supplying to leading international aid agencies and participating in global tenders. The stringent quality and regulatory standards, supported by international certifications, facilitated new customer additions and exploration of export opportunities in Europe
The Single-Centric Pilot Study of the improved TC2 TTK Chitra Titanium Heart Valves covering 40 patients has been completed and the three- year follow-up results till date show excellent performance. The Company is planning to commence pivotal studies involving around 400 patients upon receipt of necessary funding approval from BIPP and the required regulatory approvals. In view of the constraints in the availability
The stringent quality and regulatory standards, supported by international certifications, facilitated new customer additions and exploration of export opportunities in Europe and the United States. Initiated product registrations across multiple countries, which, upon completion, are expected to enable direct participation in international tenders and strengthen its global market presence. Commitment to environmenta
Heart Valves and Ortho Implants manufactured by your Company. y The male contraceptives segment offers decent volumes in both domestic and international markets and this could be leveraged to grow the business. y Considering the size of the market for food products, the Foods Business of your Company has potential for growth, both in the domestic / overseas markets.
All the official news releases are disseminated on the Company’s website. The presentations made to institutional investors or to the analysts, if any, are posted on the Company’s website. GENERAL SHAREHOLDERS INFORMATION: (a) Date, Time and Venue of the Annual General Meeting: Date : July 24, 2026 Day : Friday Time : 12 noon Mode : Through Video Conferencing (VC) and Other Audio Visual Means (OAVM) (b) Particulars o
Reasons for delayed compliance for the previous financial year 2024-25: The Company had identified in the beginning of the year 2024 itself, a Senior Officer of the Central Government, who retired in November, 2023, for appointment as an Independent Director of the Company and she had also consented for taking up this assignment as an Independent Director, subject to the approval from the Central Government. Due to t
Implemented various cost-saving initiatives across the business operations from sourcing to delivery and achieving savings through annualized contracts with major corporate suppliers and these initiatives would continue. The strategy for the year 2026-27 would be to (i) sustain and maximise production at both the factories; (ii) optimize the product mix particularly through exports and institutional business so as to
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…